Shares of Dendreon (NASDAQ:DNDN) are trading 9.5% higher Friday, up for the second consecutive session on optimism on sales of the firm’s premier and only product Provenge will rise. Revenues from its Provenge drug more than tripled in the fourth quarter to $82 million from the year-ago period. The report eased concerns that had sparked in early August when the company withdrew its 2011 guidance after demand for the drug didn’t peak as quickly as they projected.